Virios announces positive Long-COVID data for valacyclovir/celecoxib; cash $4.5M

Dogwood Therapeutics, Inc.

Female long-COVID patients showed significant improvements in fatigue, pain, and autonomic dysfunction after 14 weeks of Val/Cel vs routine care.
Company plans to meet with FDA in H2 2023 to discuss opening an IND for formal PASC treatment assessment.
Treatment well tolerated; no serious adverse events; nausea most common AE in Val/Cel group.
As of June 30, 2023, Virios had approximately $4.5M in cash and cash equivalents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.